Product Information
| Concentration | 0.2 mg/mL |
| Applications | ELISA, WB, Dot blot |
| Host Species | Goat |
| Species Reactivity | Mouse IgG Fcγ 1 |
| Physical State | Liquid |
| Suggested Dilution Range | 1:2000-1:40,000 for western blotting with ECL substrates 1:1000-1:20,000 for ELISA and Western blotting with chromogenic substrates |
| Purity | The antibody was purified from antisera by immunoaffinity chromatography using antigens coupled to agarose beads. |
| Storage Buffer | 0.01 M Sodium phosphate, 0.25 M NaCl, 50% glycerol, 3 mg/ml BSA, pH 7.6. |
| Storage Instructions | Store at -20°C. Stable for one year after shipment. |
| Stabilizer | 3 mg/ml BSA |
| Clonality | Polyclonal |
| RRID | AB_2890964 |
| Note | This product is for research use only,not for diagnostic or therapeutic use. |
Publications
| Title |
|---|
Nat Nanotechnol Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B. |
J Exp Med Japanese encephalitis virus-primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis. |
Int J Nanomedicine Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV. |
Front Immunol Protective Effect Against Toxoplasmosis in BALB/c Mice Vaccinated With Recombinant Toxoplasma gondii MIF, CDPK3, and 14-3-3 Protein Cocktail Vaccine. |
Sci Rep Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma |
Immunobiology TLR-2 agonist Pam3CSK4 has no therapeutic effect on visceral leishmaniasis in BALB/c mice and may enhance the pathogenesis of the disease |
